Related Experiment Video

Updated: Apr 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

(+)-Dehydroabietylamine derivatives target triple-negative breast cancer

Taotao Ling1, My Tran1, Miguel A González2

  • 1Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA.

European Journal of Medicinal Chemistry
|August 5, 2015
PubMed

Insights

Researchers identified a novel abietane compound that effectively inhibits triple-negative breast cancer cell growth. This compound shows promise as a new therapeutic candidate for this aggressive disease.

Area of Science:

  • Natural Product Chemistry
  • Cancer Biology
  • Medicinal Chemistry

Background:

  • Breast cancer is a leading cause of cancer death in women.
  • Triple-negative breast cancer (TNBC) lacks effective targeted therapies.
  • Estrogen receptor-positive breast cancer has targeted treatments, highlighting a need for TNBC-specific drugs.

Purpose of the Study:

  • To discover novel chemical scaffolds for targeting triple-negative breast cancer.
  • To identify natural products with selective activity against TNBC cell lines.
  • To develop new therapeutic candidates for invasive breast carcinoma.

Main Methods:

  • Phenotypic screening of terrestrial natural products against human breast carcinoma cell lines (MDA-MB-231, MA11, MCF-7).
  • Focusing on abietane natural products with preferential inhibition of TNBC cells.
  • Generating a focused library from (+)-dehydroabietylamine and evaluating lead compound 61.

Main Results:

  • Compound 61 demonstrated a promising EC50 of 9.0 μM against MDA-MB-231 cells.
  • Mechanistic studies revealed that compound 61 induces apoptosis.
  • Apoptosis induction was linked to the activation of caspase-9 and -3 and poly (ADP-ribose) polymerase (PARP) cleavage.

Conclusions:

  • Abietane derivatives represent a promising class of compounds for TNBC therapy.
  • Compound 61 is a potential therapeutic candidate warranting further investigation.
  • Targeting apoptosis pathways offers a viable strategy against triple-negative breast cancer.
Keywords:
(+)-DehydroabietylamineAbietaneApoptosisBreast cancerTriple-negative

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
835